Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Cogle

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication ForksKartika Venugopal, Yang Feng, Pawel Nowialis, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Nature Communications|July 29, 2025
Epigenomic diagnosis and prognosis of Acute Myeloid LeukemiaFrancisco Marchi, Vivek M Shastri, Richard J Marrero, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication ForksKartika Venugopal, Yang Feng, Pawel Nowialis, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
International Journal of Laboratory Hematology|November 21, 2020
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromesJay L Patel, Mehrdad Abedi, Christopher R Cogle, et al.
Transplantation and Cellular Therapy|April 22, 2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to CareBenjamin Tomlinson, Marcos de Lima, Christopher R Cogle, et al.
Nature Communications|July 29, 2025
Epigenomic diagnosis and prognosis of Acute Myeloid LeukemiaFrancisco Marchi, Vivek M Shastri, Richard J Marrero, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Pageof 14